Intervention

MitoQ

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting2

Common conditions18

Lead sponsors shown6

Clinical trials

8 shown

Effects of an Antioxidant Supplement on Blood Vessel HealthNCT06424756 · 2024-07-01

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial DysfunctionNCT06191965 · 2024-06-01

Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)NCT05605548 · 2023-02-16

Mitochondria Oxidative Stress and Vascular Health StudyNCT05561556 · 2022-12-06

The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular FunctionNCT04334135 · 2020-10-02

Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) PatientsNCT03514875 · 2019-11-11

Chronic Kidney Disease and Heart Failure With Preserved Ejection Fraction: The Role of Mitochondrial DysfunctionNCT03960073 · 2019-07-31

A Trial of MitoQ for the Treatment of People With Parkinson's DiseaseNCT00329056 · 2006-05-01

Common conditions

Alzheimer Disease, Early Onset1 Blood Pressure1 Cardiovascular Diseases1 Cardiovascular Risk Factor1 Chronic Obstructive Pulmonary Disease1 Cognitive Impairment1 Healthy1 Heart Failure With Preserved Ejection Fraction1 Hypertension1 Mild Cognitive Impairment1 Mitochondrial Alteration1 Parkinson's Disease1 Racial Disparities1 Racism1 Renal Function1 Renal Insufficiency, Chronic1 Schizophrenia and Related Disorders1 Vascular Diseases1

Leading sponsors

Auburn University2 Virginia Commonwealth University2 Antipodean Pharmaceuticals, Inc.1 Mclean Hospital1 University of Georgia1 University of Nebraska1

Trial status mix

COMPLETED3

RECRUITING2

TERMINATED1

UNKNOWN1

WITHDRAWN1

Phase mix

NA4

PHASE23

EARLY_PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.